NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

NAN - NANOSONICS LIMITED
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.43
Index: ASX200 | ASX300 | ALL-ORDS
Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$4.26
05 Dec |
OPEN $4.13 |
HIGH $4.27 |
372,851 LOW $4.10 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | 6.6 | 5.2 | xxx |
DPS (cps) | xxx | 0.0 | 0.0 | xxx |
EPS Growth | xxx | 100.0% | - 22.0% | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | 85.0 | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | 0.0% | 0.0% | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 6.6 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 167.5 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 54.2 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 23.3 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 11.87 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 13.14 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 12.44 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 9.47 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 13.14 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 11.08 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 19.7 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 3 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 8 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 11 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 112 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 8.75 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross

Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 3.6 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 2.13 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 42 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 108 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 27 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 1 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
NAN STOCK CHART

FNArena News on NAN
1 |
Australian Broker Call *Extra* Edition – Nov 15, 2023Nov 15 2023 - Daily Market Reports |
2 |
ESG Focus: Day Of The TRIFRSNov 09 2023 - ESG Focus |
3 |
Rudi’s View: A Market Of ContradictionsNov 01 2023 - Rudi's View |
4 |
Rudi’s View: Outlook Negative, With Plenty Of Silver LiningsSep 06 2023 - Rudi's View |
5 |
Weekly Ratings, Targets, Forecast Changes – 25-08-23Aug 28 2023 - Weekly Reports |
Latest Medical Equipment & Devices News
1 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |
2 |
Dr Boreham’s Crucible: CyclopharmOct 09 2023 - Small Caps |
3 |
Dr Boreham’s Crucible: PainchekSep 11 2023 - Small Caps |
4 |
Margins Signal Integral Diagnostics RecoverySep 07 2023 - Australia |
5 |
ResMed: Finding A Base?Aug 15 2023 - Technicals |
6 |
August Turns ResMed Into Nigel NoMatesAug 09 2023 - Australia |
7 |
Dr Boreham’s Crucible: Lumos DiagnosticsJun 19 2023 - Small Caps |
8 |
Fisher & Paykel Healthcare: Lower Margin, Higher SpendingMay 30 2023 - Australia |
9 |
Dr Boreham’s Crucible: ImpedimedMay 08 2023 - Small Caps |
10 |
Treasure Chest: ResMed’s Benevolent MonopolyMay 01 2023 - Treasure Chest |